autologous cultured chondrocytes on porcine collagen membrane
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
18
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Articular Cartilage Defects
Conditions
Articular Cartilage Defects
Trial Timeline
Dec 1, 2010 → Mar 1, 2015
NCT ID
NCT01251588About autologous cultured chondrocytes on porcine collagen membrane
autologous cultured chondrocytes on porcine collagen membrane is a pre-clinical stage product being developed by Vericel for Articular Cartilage Defects. The current trial status is completed. This product is registered under clinical trial identifier NCT01251588. Target conditions include Articular Cartilage Defects.
Hype Score Breakdown
Clinical
5
Activity
2
Company
5
Novelty
2
Community
1
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06915233 | Phase 3 | Recruiting |
| NCT01251588 | Pre-clinical | Completed |
| NCT00719576 | Phase 3 | Completed |
Competing Products
6 competing products in Articular Cartilage Defects
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| Abatacept | Bristol Myers Squibb | Phase 3 | 76 |
| Certolizumab Pegol (CZP) + Certolizumab Pegol (CZP) | UCB | Phase 3 | 74 |
| autologous cultured chondrocytes on porcine collagen membrane | Vericel | Phase 3 | 72 |
| Carticel (autologous cultured chondrocyte) implantation | Vericel | Pre-clinical | 18 |
| Carticel (autologous cultured chondrocyte) implantation | Vericel | Approved | 80 |